Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-09
2006-05-09
Morris, Patricia L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S276700
Reexamination Certificate
active
07041684
ABSTRACT:
The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective β3receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and methods of treating Type II diabetes and obesity, comprising administering to a mammal in need thereof compounds of formula (I).
REFERENCES:
patent: 4032575 (1977-06-01), Ikezaki et al.
patent: 4140789 (1979-02-01), Jaeggi et al.
patent: 4235919 (1980-11-01), Berthold
patent: 4288452 (1981-09-01), Sombroek et al.
patent: 4309443 (1982-01-01), Smith et al.
patent: 4310527 (1982-01-01), Jaeggi
patent: 4338333 (1982-07-01), Ainsworth et al.
patent: 4346093 (1982-08-01), Friebe et al.
patent: 4367235 (1983-01-01), Ross et al.
patent: 4385066 (1983-05-01), Ainsworth et al.
patent: 4391826 (1983-07-01), Mills et al.
patent: 4396627 (1983-08-01), Ainsworth et al.
patent: 4432993 (1984-02-01), Ferris
patent: 4478849 (1984-10-01), Ainsworth et al.
patent: 4497813 (1985-02-01), Ostermayer et al.
patent: 4503067 (1985-03-01), Wiedemann et al.
patent: 4513001 (1985-04-01), Joannic et al.
patent: 4636511 (1987-01-01), Ostermayer et al.
patent: 4652679 (1987-03-01), Alig et al.
patent: 4697022 (1987-09-01), Leinert
patent: 4727067 (1988-02-01), Ostermayer et al.
patent: 4751246 (1988-06-01), Philion
patent: 4772631 (1988-09-01), Holloway et al.
patent: 4892886 (1990-01-01), Alig et al.
patent: 4940800 (1990-07-01), Bertolini et al.
patent: 4960783 (1990-10-01), Bonse et al.
patent: 4977148 (1990-12-01), Holloway et al.
patent: 5013761 (1991-05-01), Beedle et al.
patent: 5064863 (1991-11-01), Alig et al.
patent: 5166218 (1992-11-01), Alig et al.
patent: 5254595 (1993-10-01), Guzzi et al.
patent: 5321036 (1994-06-01), Sher
patent: 5393772 (1995-02-01), Yue et al.
patent: 5420294 (1995-05-01), Beedle et al.
patent: 5453436 (1995-09-01), Ohlstein
patent: 5488151 (1996-01-01), Baroni et al.
patent: 5534640 (1996-07-01), Tegeler et al.
patent: 5541197 (1996-07-01), Fisher et al.
patent: 5541204 (1996-07-01), Sher et al.
patent: 5561142 (1996-10-01), Fisher et al.
patent: 5574164 (1996-11-01), Tegeler et al.
patent: 5776983 (1998-07-01), Washburn et al.
patent: 6140352 (2000-10-01), Crowell et al.
patent: 636856 (1983-06-01), None
patent: 4040186 (1991-06-01), None
patent: 0040000 (1981-11-01), None
patent: 0052963 (1982-06-01), None
patent: 0061907 (1982-10-01), None
patent: 0063004 (1982-10-01), None
patent: 0066351 (1982-12-01), None
patent: 0068669 (1983-01-01), None
patent: 0070134 (1983-01-01), None
patent: 0082665 (1983-06-01), None
patent: 0089154 (1983-09-01), None
patent: 0091749 (1983-10-01), None
patent: 0095827 (1983-12-01), None
patent: 0099707 (1984-02-01), None
patent: 00102213 (1984-03-01), None
patent: 0171702 (1986-02-01), None
patent: 0196849 (1986-10-01), None
patent: 0211721 (1987-02-01), None
patent: 0236624 (1987-09-01), None
patent: 0328251 (1989-01-01), None
patent: 0345056 (1989-06-01), None
patent: 0386920 (1990-09-01), None
patent: 0500443 (1992-08-01), None
patent: 0611003 (1994-02-01), None
patent: 0659737 (1994-12-01), None
patent: 0642787 (1995-03-01), None
patent: 0687472 (1995-12-01), None
patent: 0714663 (1996-06-01), None
patent: 1391828 (1975-04-01), None
patent: 1532380 (1978-11-01), None
patent: 1549945 (1979-08-01), None
patent: 1571231 (1980-07-01), None
patent: 0436435 (1991-07-01), None
patent: 0455006 (1991-11-01), None
patent: WO92/18461 (1992-10-01), None
patent: 0565317 (1993-10-01), None
patent: WO93/22277 (1993-11-01), None
patent: WO94/02493 (1994-02-01), None
patent: WO94/03425 (1994-02-01), None
patent: WO94/29290 (1994-12-01), None
patent: WO9429290 (1994-12-01), None
patent: WO95/01170 (1995-01-01), None
patent: WO95/04047 (1995-02-01), None
patent: WO96/04234 (1996-02-01), None
patent: WO96/04234 (1998-02-01), None
Tejani-Butt and Brunswick. “Synthesis an β-Adrenergic Receptor Blocking Potency of 1-(Substituted amino)-3-(4-indolyloxy) propan-2-ols” J. Med. Chem 29:1524-1527 (1986).
Bürgisser, et al. “Alternative Explanation for the Apparent Two Step Binding Kinetics of High-Affinity Racemic Antagonist Radioligands” Molecular Pharmacology 19:509-512 (1981).
Marinetti, et al. “Beta-Adrenergic Receptors of Human Leukocytes” Biochemical Pharmacology 32(13):2033-2043 (1983).
Howe, et al. “Selective β3-adrenergic agonists of brown adipose tissue and thermogenesis” Chemical Abstracts 117:40209r (1992).
Jimenez, et al. “1-Thymoxy-2-propanolamines” Chemical Abstracts 86:29468v (1977).
Izquierdo Sanjose, et al., “Morpholine derivative and its salts” Chemical Abstracts 90:186971d (1979).
G. Neugebauer and P. Neubert, Metabolism and Pharmacokinetcs 16(4):257-260 (1991).
S.L. Heald, et al. “Synthesis of Iodine-125 labeled 14-(4-Azidobenzyl) Carazolol: A Potent Beta Adrenergic Photoaffinity Probe” J. Med. Chem. 26(6):832-838 (1983).
R.G.L. Shorr, et al. “The Beta-Adrenergic Receptor: Rapid Purification and Covalent Labeling by Photoaffinity Crosslinking” Proc. Natl. Acad. Sci. USA 79:2778-2782 (1982).
B. Ehmer, et al. “Influence of Carvedilol on Blood Glucose and Glycohaemoglobin A1 in Non-Insulin Dependent Diabetes” Drugs 36(6): 136-140 (1988).
Rito Christopher J.
Shuker Anthony J.
Eli Lilly and Company
Morris Patricia L.
Voy Gilbert T.
LandOfFree
Selective β 3 adrenergic agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective β 3 adrenergic agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective β 3 adrenergic agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3633224